Locations:
Search IconSearch
April 29, 2019/Cancer/Radiation Oncology

New Guidelines Aid Management of the Neck in Oral Cavity and Oropharynx Cancers

Anatomically close, etiologically different cancers

oropharynx_650x450

New clinical practice guidelines from the American Society of Clinical Oncology (ASCO) offer a systematic, evidence-based approach to managing the neck in squamous cell carcinomas of the oral cavity and of the oropharynx.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The guidelines address the two types of cancers separately, since they’re etiologically quite different despite their close anatomical proximity. Oral cavity cancer is primarily associated with traditional risk factors such as smoking, chewing tobacco, and alcohol, whereas oropharynx cancer now is mostly due to the epidemic of human papillomavirus (HPV).

The document incorporates the recent emergence of positron emission tomography (PET) for evaluation of the neck.

According to Cleveland Clinic radiation oncologist Shlomo A. Koyfman, MD, co-chair of the guideline writing panel, “There was a need to clarify what should we do with the neck for oropharynx cancer in the era of modern imaging and knowing about HPV, and what should we do for oral cavity cancer, which is kind of a different disease.”

Evidence-based guidelines

For both cancers, the guidelines address indications for, and hallmarks of, high-quality neck dissections. For oral cavity cancers, the document advises on indications for postoperative radiotherapy or chemotherapy, and whether radiotherapy alone is sufficient or a neck dissection is indicated. And for oropharynx cancer, recommendations cover operative versus nonoperative primary management, and criteria to define an incomplete response to chemoradiation that would warrant a salvage neck dissection.

Developed by a 12-expert panel, the guidelines are based on evidence from 124 relevant studies. The group devised six clinical scenarios — three for each cancer type — and generated recommendations for each one. The intended audience is medical oncologists, radiation oncologists, nurses, speech pathologists, oncology pharmacists and patients.

Advertisement

Previous guidelines have addressed aspects of these cancers, including HPV testing, larynx preservation and radiation therapy, but this document is the first to focus specifically on surgical and nonsurgical management of the neck in both cancers, Dr. Koyfman notes. “It wasn’t as much that a ton of new evidence came out, but that given the changing disease epidemiology and the changing use of PET scanning, we wanted to create a systematic approach for managing them.”

The guidelines are clear, for example, that surgery rather than radiation is the optimal primary mode for initial management of the neck in oral cavity cancer. On the other hand, surgery isn’t the best approach for bulky nodes or bulky neck disease with probable extranodal extension, where radiation and chemotherapy are likely to be necessary afterward.

“Knowing when to choose surgery vs. radiation and how to do it optimally will help people most,” according to Dr. Koyfman.

Another aspect of the document addresses the practice of removing at least 18 nodes, now used as a quality metric for head and neck squamous cell carcinoma surgery due to its association with overall improved survival and lower local-regional failure rates. “The guidelines go over what areas of the neck you should focus on when you do this,” Dr. Koyfman says.

Consistency across guidelines

The document is written to be consistent with the recent American Society for Radiation Oncology oropharynx management guidelines that ASCO endorsed within the last year. “So now there are a couple of guidelines that have a consistent message about how to think about what to do with the lymph nodes in the neck, both in terms of treating and following after treatment.”

Advertisement

These guidelines will be quite useful for tumor board meetings, Dr. Koyfman says. “If you just print them out, keep them in clinic, hang them up, bring them to tumor board, they should serve as an important reference to try and help standardize how we approach some of these problems. I think they can give guidance when there might be multiple reasonable things to do, and it might be difficult to choose. This might help you make the most evidence-based recommendation.”

Advertisement

Related Articles

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Lobular breast cancer cells
December 22, 2025/Cancer/Innovations
Comprehensive Lobular Breast Cancer Program Addresses Often-Misunderstood Disease

Care paths and research initiatives aim to answer unmet clinical needs

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Ad